Agios Pharmaceuticals aims to conduct initial public offering of stock

Proceeds slated for clinical development and research and development

By Devika Patel

Knoxville, Tenn., June 10 - Agios Pharmaceuticals, Inc. will price an initial public offering of its common stock with a greenshoe option, according to a Form S-1 filed Monday with the Securities and Exchange Commission. The company expects its shares will trade on the Nasdaq under the symbol "AGIO." The deal could raise up to $86 million.

J.P. Morgan, Goldman, Sachs & Co., Cowen and Co. and Leerink Swann are assisting.

Proceeds will be used for clinical development, research and development, working capital and other general corporate purposes, including potential acquisitions.

The biopharmaceutical company is based in Cambridge, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.